Intracranial hemorrhage represents a severe complication of brain arteriovenous malformation treatment. The aim of this cohort was to report the rate of hemorrhagic complications after transvenous endovascular embolization and analyze the potential angioarchitectural risk factors as well as clinical outcomes. During an 11-year period, 57 patients underwent transvenous endovascular embolization. All cases of hemorrhagic complications were identified. We analyzed the following variables: sex, age, hemorrhagic presentation, Spetzler-Martin grade, size of the AVM before the transvenous treatment, number of venous collectors, pattern of drainage, presence of dilated veins, and technical aspects. Univariate and multivariate multiple regression analyses were performed to evaluate the potential risk factors for procedure-related hemorrhagic complications. Hemorrhagic complications (either intraprocedural or periprocedural) unrelated to a perforation due to micronavigation occurred in 8 (14.0%) procedures. Significant (mRS > 2) and persistent neurologic deficits were present in 2 (3.5%) patients at 6-month control. Larger nidi, especially >3 cm (P = .03), and a larger number of venous collectors have shown a statistically significant correlation with hemorrhagic complications. Only the number of venous collectors was identified as an independent predictor of hemorrhagic complications in the multivariate analysis (OR, 8.7; 95% confidence interval, 2.2-58.2) (P = .006). Larger nidus sizes and an increased number of venous collectors may increase the risk of hemorrhagic complications when implementing transvenous endovascular treatment of AVMs. The technique is effective and promising, especially with small nidi and single venous collectors.

BACKGROUND AND PURPOSE: Dural AVFs located in the posterior fossa are a rare entity. The objectives of the study were to analyze the anatomy of dural AVFs, their endovascular treatment strategies, and clinical outcomes. MATERIALS AND METHODS: Two centers retrospectively selected patients treated between January 2009 and June 2018 having posterior fossa dural AVFs. We collected patient demographics, clinical presentation, arterial and venous outflow anatomy of the dural AVFs, and treatment outcomes. RESULTS: Twenty-six patients treated endovascularly for posterior fossa dural AVFs, type III, IV, or V, were included. One hundred percent of the dural AVFs were occluded. A transarterial approach was performed in 23 dural AVFs (88.5%); a combined transarterial and transvenous approach, for 2 dural AVFs (7.7%); and a transvenous approach alone, for 1 dural AVF (3.8%). The middle meningeal artery was the most common artery chosen to inject embolic liquid (46%, 12/26). Procedure-related morbidity was 15.4% at 24 hours, 7.7% at discharge, and 0% at 6 months. Procedure-related mortality was 0%. CONCLUSIONS: Endovascular treatment offers high occlusion rates for posterior fossa dural AVFs with low morbidity and mortality rates. The arterial approach is the first-line preferred approach, even if a transvenous or combined approach would be a safe and effective option for patients with favorable anatomy. Twenty-six patients treated endovascularly for posterior fossa dural AVFs, type III, IV, or V, were included in this study. One hundred percent of the dural AVFs were occluded. A transarterial approach was performed in 23 dural AVFs; a combined transarterial and transvenous approach, in 2 dural AVFs; and a transvenous approach alone, in 1 dural AVF. The middle meningeal artery was the most common artery chosen to inject embolic liquid (12/26). Procedure-related morbidity was 15.4% at 24 hours, 7.7% at discharge, and 0% at 6 months. Procedure-related mortality was 0%. The authors conclude that endovascular treatment offers high occlusion rates for posterior fossa dural AVFs with low morbidity and mortality rates.

Introduction: Patellofemoral osteoarthritis (PFOA) remains a therapeutic challenge with few effective non-surgical options. Objective: The aim of this study was to evaluate the feasibility, safety, and preliminary outcomes of ultrasound (US)-guided tibial endplate aspiration and intra-articular injection of bone marrow concentrate (BMC) in patients with isolated PFOA. Methods: In this retrospective case series, seven consecutive patients with symptomatic PFOA unresponsive to conservative therapy were treated with US-guided tibial endplate aspiration followed by intra-articular BMC injection. Clinical outcomes were assessed with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at baseline and 12 months. MRI with T2 mapping was performed to evaluate cartilage structure. BMC composition was analyzed, including colony-forming unit fibroblast (CFU-F) assays. Results: The procedures were feasible in all cases, and no adverse events occurred. WOMAC scores improved significantly from 21.7 ± 17.3 at baseline to 9.0 ± 9.3 at 12 months (p = 0.030). MRI showed a mean relative increase of 25.4% ± 43.5% in healthy cartilage volume, though this was not statistically significant (p = 0.49). Correlation analyses revealed no consistent association between clinical response and cellular composition, including estimated MSC dose. Conclusions: This small retrospective series suggests that US-guided tibial endplate aspiration and intra-articular BMC injection are safe, technically feasible, and may provide clinical benefit in isolated PFOA. Larger controlled studies are needed to confirm these preliminary findings.